Spyre Therapeutics (SYRE) Other Non Operating Income (2015 - 2026)
Spyre Therapeutics posted quarterly Other Non Operating Income of -$30.4 million for Q1 2026, down 1428.04% year-on-year from $2.3 million in Q1 2025, and down 142.93% on a QoQ basis from -$12.5 million in Q4 2025.
Spyre Therapeutics (SYRE) has 12 years of Other Non Operating Income data on file, last reported at -$30.4 million in Q1 2026.
- For the quarter ending Q1 2026, Other Non Operating Income fell 1428.04% year-over-year to -$30.4 million; the trailing twelve-month figure through Mar 2026 stood at -$3.2 million (up 82.24% YoY), and the FY2025 full-year result was $29.5 million, up 242.22% from the prior year.
- Other Non Operating Income for Q1 2026 stood at -$30.4 million, down from -$12.5 million in the prior quarter.
- Across five years, Other Non Operating Income topped out at $40.3 million in Q3 2025 and bottomed at -$30.4 million in Q1 2026.
- The 5-year median for Other Non Operating Income is -$72000.0 (2023), against an average of -$2.4 million.
- Peak annual rise in Other Non Operating Income reached 9658.33% in 2023, while the deepest fall reached 66750.0% in 2023.
- A 5-year view of Other Non Operating Income shows it stood at -$32000.0 in 2022, then tumbled by 66750.0% to -$21.4 million in 2023, then soared by 96.18% to -$818000.0 in 2024, then slumped by 1427.75% to -$12.5 million in 2025, then tumbled by 142.93% to -$30.4 million in 2026.
- The last three Other Non Operating Income figures came in at -$30.4 million (Q1 2026), -$12.5 million (Q4 2025), and $40.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Spyre Therapeutics | 5.55 Bn | 5.55 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -30.36 Mn |
| Dec 31, 2025 | -12.50 Mn |
| Sep 30, 2025 | 40.33 Mn |
| Jun 30, 2025 | -656,000.00 |
| Mar 31, 2025 | 2.29 Mn |
| Dec 31, 2024 | -818,000.00 |
| Sep 30, 2024 | -18.80 Mn |
| Jun 30, 2024 | -610,000.00 |
| Mar 31, 2024 | -483,000.00 |
| Dec 31, 2023 | -21.39 Mn |
| Sep 30, 2023 | 2.34 Mn |
| Jun 30, 2023 | -8,000.00 |
| Mar 31, 2023 | -72,000.00 |
| Dec 31, 2022 | -32,000.00 |
| Sep 30, 2022 | 24,000.00 |
| Jun 30, 2022 | 5,000.00 |
| Mar 31, 2022 | -30,000.00 |
| Dec 31, 2021 | -15,000.00 |
| Sep 30, 2021 | -24,000.00 |
| Jun 30, 2021 | -52,000.00 |
| Mar 31, 2021 | -31,000.00 |
| Dec 31, 2020 | 18,000.00 |
| Sep 30, 2020 | 2,000.00 |
| Jun 30, 2020 | -19,000.00 |
| Mar 31, 2020 | -6,000.00 |
| Dec 31, 2019 | -18,000.00 |
| Sep 30, 2019 | -12,000.00 |
| Jun 30, 2019 | -16,000.00 |
| Mar 31, 2019 | -17,000.00 |
| Dec 31, 2018 | -20,000.00 |
| Sep 30, 2018 | -13,000.00 |
| Jun 30, 2018 | -7,000.00 |
| Mar 31, 2018 | -17,000.00 |
| Dec 31, 2017 | -7,000.00 |
| Sep 30, 2017 | -12,000.00 |
| Jun 30, 2017 | -12,000.00 |
| Mar 31, 2017 | -11,000.00 |
| Dec 31, 2016 | -12,000.00 |
| Sep 30, 2016 | -9,000.00 |
| Jun 30, 2016 | -9,000.00 |
| Mar 31, 2016 | -6,000.00 |
| Dec 31, 2015 | -1,000.00 |
| Sep 30, 2015 | -1,000.00 |